Aileron Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Rein Therapeutics

11/05/2021 23:37

* Aileron Therapeutics Inc  ALRN.OQ  reported a quarterly
adjusted loss of 8 cents​​ per share for the quarter ended
in March. The mean expectation of three analysts for the quarter
was for a loss of 5 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* Aileron Therapeutics Inc's reported EPS for the quarter was a
loss of 8 cents​.
* The mean earnings estimate of analysts had risen by
about 44.8% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Aileron Therapeutics Inc shares had fallen by 20.3% this
quarter and gained 9.6% so far this year.
* The company reported a quarterly loss of $6.98 million.
* Wall Street's median 12-month price target for Aileron
Therapeutics Inc is $3.50 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 11 at 10:37 p.m. GMT.
​All figures in US dollars